Attorneys handling mass tort litigation in October 2026 face two major settlements, active federal trials, and strict filing deadlines. Mass torts, grouped injury claims against a common defendant, are moving fastest in talc, Depo-Provera, Camp Lejeune, and social-media cases.
The key takeaway is split progress. Some dockets seek closure through settlement talks, while large drug and chemical dockets remain in expert review and discovery. Readers with a possible claim should check deadlines and proof now.
Table of Contents
- Which settlements advanced this summer?
- Which trials and talks matter in October?
- Where do drug and chemical MDLs stand?
- What agency action should attorneys watch?
- What should potential claimants do now?
Which settlements advanced this summer?
Johnson and Johnson agreed July 27, 2026 to pay about $5.5 billion to resolve roughly 76,000 ovarian-cancer talc suits in federal and state courts. Reuters reported the deal requires 95 percent claimant participation, in its account of the $5.5 billion talc resolution. Depo-Provera litigation also reached a turning point. Before Judge M. Casey Rodgers, MDL 3140 reached a confidential Master Settlement Agreement July 21, 2026 for federal and New York meningioma claims.
TortAdvisor, citing MDL orders and the JPML report, places 6,403 federal cases pending Sept. 1, 2026, in its Depo-Provera case-status update. Both deals still need claimant action. Talc claimants face a participation threshold. Depo-Provera claimants face registration and proof requirements.
Which trials and talks matter in October?
Camp Lejeune judges ordered the parties to pursue a global settlement framework by Oct. 30, 2026. Pretrial conferences for four kidney-cancer cases occurred Sept. 9-10, with bench trials set Nov. 9 and 16, according to Public Radio East in its report on settlement talks and trial scheduling. Federal social-media litigation entered week four of trial Sept.
8, 2026 before Judge Yvonne Gonzalez Rogers. About 3,137 personal-injury claims remain open after Meta's $17.1 billion state-attorney-general settlement. LawyersTrend reported the trial status Sept. 11, 2026. These are different paths. Camp Lejeune uses judge-decided bench trials tied to settlement talks. Social-media claims use a jury trial on personal-injury liability.
Where do drug and chemical MDLs stand?
Hair-relaxer MDL 3060 before Judge Mary Rowland held 12,129 federal cases Sept. 1, 2026. On Sept. 1 she cut the bellwether pool from ten to five, with second-wave discovery running through July 15, 2027 and no trial date set. Fob James Law Firm reported the figures from the JPML report. AFFF MDL 2873 before Judge Richard Gergel held 15,264 personal-injury cases Sept. 1, 2026.
📨 Get Free Mass Tort Guides Alerts
Free · No spam · Unsubscribe anytime
The Oct. 2025 kidney-cancer bellwether was vacated. A 28-case pool involving kidney, testicular, thyroid and ulcerative-colitis claims remains in expert discovery. GLP-1 litigation totaled 4,238 federal filings Sept. 1, 2026, including 4,022 gastroparesis cases in MDL 3094. Judge Karen Marston heard general-causation expert arguments Sept. 14-18, 2026, with a ruling still pending. Causation rulings often shape which cases move forward.
What agency action should attorneys watch?
On Sept. 2, 2026, FDA issued a warning letter to Jabil's Pharmaceutics International sterile-injectable facility. Simply Wall St, reporting on the FDA letter, describes significant CGMP violations including recurring fungal contamination and inadequate investigations. The letter does not create a mass tort.
It documents manufacturing-quality findings at one sterile-drug site. Attorneys track such notices because contamination and failed investigations can support product-liability review. Clients should not assume an FDA letter proves individual injury. Use it as a prompt to ask about lot numbers, pharmacy records, and adverse-event reports.
What should potential claimants do now?
Hair-relaxer and AFFF have no global personal-injury settlement or completed bellwether verdict. That means waiting for a check is the wrong plan. Fob James Law Firm notes Depo-Provera registration closes Nov.
30, 2026, while Camp Lejeune elective-option disputes faced a Sept. 27 deadline. Act early and preserve proof. Attorneys generally need dates of use or exposure, diagnosis records, and product identification.
- List each product, prescription, duty station, or exposure site with dates
- Save pharmacy slips, labels, medical scans, pathology reports, and work records
- Write a short timeline of symptoms, doctors, and missed work
- Do not discard containers, military orders, or employment records
- Ask an attorney promptly whether your filing deadline has passed
You Might Also Like
- What Is New With Verdicts Mass Tort Litigation in September 2026? Latest court filings and agency notices and Key Takeaways
- What Is New With Pharmaceutical Lawsuits Mass Tort Litigation in September 2026? Latest court filings and agency notices and Key Takeaways
- What Is New With Medical Device Lawsuits Mass Tort Litigation in September 2026? Latest court filings and agency notices and Key Takeaways